These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 29156678)
1. Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Burgermeister E; Höde P; Betge J; Gutting T; Merkel A; Wu W; Tänzer M; Mossner M; Nowak D; Magdeburg J; Rückert F; Sticht C; Breitkopf-Heinlein K; Schulte N; Härtel N; Belle S; Post S; Gaiser T; Heppner BI; Behrens HM; Röcken C; Ebert MPA Oncotarget; 2017 Oct; 8(49):84714-84728. PubMed ID: 29156678 [TBL] [Abstract][Full Text] [Related]
2. Expression of TUSC3 and its prognostic significance in colorectal cancer. Zhu YF; Dong M Pathol Res Pract; 2018 Sep; 214(9):1497-1503. PubMed ID: 30115537 [TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. Kratochvílová K; Horak P; Ešner M; Souček K; Pils D; Anees M; Tomasich E; Dráfi F; Jurtíková V; Hampl A; Krainer M; Vaňhara P Int J Cancer; 2015 Sep; 137(6):1330-40. PubMed ID: 25735931 [TBL] [Abstract][Full Text] [Related]
4. Structural basis of substrate specificity of human oligosaccharyl transferase subunit N33/Tusc3 and its role in regulating protein N-glycosylation. Mohorko E; Owen RL; Malojčić G; Brozzo MS; Aebi M; Glockshuber R Structure; 2014 Apr; 22(4):590-601. PubMed ID: 24685145 [TBL] [Abstract][Full Text] [Related]
5. Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Pils D; Horak P; Vanhara P; Anees M; Petz M; Alfanz A; Gugerell A; Wittinger M; Gleiss A; Auner V; Tong D; Zeillinger R; Braicu EI; Sehouli J; Krainer M Cancer; 2013 Mar; 119(5):946-54. PubMed ID: 23096450 [TBL] [Abstract][Full Text] [Related]
6. TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. Horak P; Tomasich E; Vaňhara P; Kratochvílová K; Anees M; Marhold M; Lemberger CE; Gerschpacher M; Horvat R; Sibilia M; Pils D; Krainer M Sci Rep; 2014 Jan; 4():3739. PubMed ID: 24435307 [TBL] [Abstract][Full Text] [Related]
7. Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. Vaňhara P; Horak P; Pils D; Anees M; Petz M; Gregor W; Zeillinger R; Krainer M Int J Oncol; 2013 Apr; 42(4):1383-9. PubMed ID: 23404293 [TBL] [Abstract][Full Text] [Related]
8. MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3. Yufeng Z; Ming Q; Dandan W Front Genet; 2021; 12():738559. PubMed ID: 34733314 [No Abstract] [Full Text] [Related]
9. Siri G; Mosallaei M; Ehtesham N; Rahimi H; Mazarei M; Nasrollahzadeh Sabet M; Behroozi J Adv Biomed Res; 2023; 12():174. PubMed ID: 37564442 [TBL] [Abstract][Full Text] [Related]
10. TUSC3: functional duality of a cancer gene. Vašíčková K; Horak P; Vaňhara P Cell Mol Life Sci; 2018 Mar; 75(5):849-857. PubMed ID: 28929175 [TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of Duppel U; Woenckhaus M; Schulz C; Merk J; Dietmaier W Oncol Lett; 2016 Oct; 12(4):3004-3012. PubMed ID: 27698890 [TBL] [Abstract][Full Text] [Related]
12. TUSC3: a novel tumour suppressor gene and its functional implications. Yu X; Zhai C; Fan Y; Zhang J; Liang N; Liu F; Cao L; Wang J; Du J J Cell Mol Med; 2017 Sep; 21(9):1711-1718. PubMed ID: 28272772 [TBL] [Abstract][Full Text] [Related]
13. Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer. Patnaik S; Anupriya Front Pharmacol; 2019; 10():588. PubMed ID: 31244652 [TBL] [Abstract][Full Text] [Related]
14. LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer. Kou C; Zhou T; Han X; Zhuang H; Qian H Biochem Biophys Res Commun; 2015 Aug; 464(2):519-25. PubMed ID: 26159916 [TBL] [Abstract][Full Text] [Related]
15. TUSC3 as a potential biomarker for prognosis in clear cell renal cell carcinoma. Yan Y; Chen Z; Liao Y; Zhou J Oncol Lett; 2019 Jun; 17(6):5073-5079. PubMed ID: 31186719 [TBL] [Abstract][Full Text] [Related]
16. Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. Jao TM; Tsai MH; Lio HY; Weng WT; Chen CC; Tzeng ST; Chang CY; Lai YC; Yen SJ; Yu SL; Yang YC Int J Cancer; 2014 Dec; 135(11):2593-603. PubMed ID: 24740680 [TBL] [Abstract][Full Text] [Related]
17. A defect in the TUSC3 gene is associated with autosomal recessive mental retardation. Garshasbi M; Hadavi V; Habibi H; Kahrizi K; Kariminejad R; Behjati F; Tzschach A; Najmabadi H; Ropers HH; Kuss AW Am J Hum Genet; 2008 May; 82(5):1158-64. PubMed ID: 18452889 [TBL] [Abstract][Full Text] [Related]
18. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854 [TBL] [Abstract][Full Text] [Related]
19. Down-regulation of TCF21 by hypermethylation induces cell proliferation, migration and invasion in colorectal cancer. Dai Y; Duan H; Duan C; Zhou R; He Y; Tu Q; Shen L Biochem Biophys Res Commun; 2016 Jan; 469(3):430-6. PubMed ID: 26435499 [TBL] [Abstract][Full Text] [Related]
20. Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. Li VS; Yuen ST; Chan TL; Yan HH; Law WL; Yeung BH; Chan AS; Tsui WY; So S; Chen X; Leung SY Gastroenterology; 2009 Jul; 137(1):176-87. PubMed ID: 19303019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]